Objective To analyze the value of combined detection of serum CEA, CA153 and CA125 in the diagnosis of breast cancer.

Methods Seventy-two breast cancer patients were selected as the breast cancer group. Sixty-eight patients with benign breast disease during the same period were selected as the benign breast disease group. 70 healthy volunteers with routine physical examination at the same time were randomly selected as the healthy control group. Three groups of subjects were tested for serum CEA, CA153 and CA125 to analyze the diagnostic value of three tumor markers for breast cancer.

Results The serum levels of CEA, CA153 and CA125 in patients with breast cancer were significantly higher than thosewith benign breast disease and healthy controls (P ＜ 0.01), there was no significant difference in serum CEA, CA153 and CA125 levels between benign breast disease group and healthy control group (P ＞ 0.05). The positive detection rates of serum CEA, CA153, CA125 and their combined detection in the observation group were 50.78% (38/72), 68.06% (49/72), 59.72% (43/72) and 80.56% (58/72), respectively. The positive detection rate was significantly higher than that in the benign breast disease group and the control group, and the difference was statistically significant (P ＜ 0.01). ROC curve analysis showed that the curve areas of serum CEA, CA153, CA125 and their combined detection were 0.684, 0.763, 0.623 and 0.841, respectively.

Conclusion In the diagnosis of breast cancer, the combined detection of serum CEA, CA153 and CA125 can improve the detection rate of breast cancer, which is worthy to be popularized in clinical application.